- Home
- SKK vs ABP Comparison
SKK vs ABP Comparison
Compare SKK & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKK
- ABP
- Stock Information
- Founded
- SKK 2013
- ABP 2004
- Country
- SKK Singapore
- ABP United States
- Employees
- SKK N/A
- ABP N/A
- Industry
- SKK
- ABP Biotechnology: Pharmaceutical Preparations
- Sector
- SKK
- ABP Health Care
- Exchange
- SKK NYSE
- ABP Nasdaq
- Market Cap
- SKK 12.3M
- ABP 14.3M
- IPO Year
- SKK 2024
- ABP N/A
- Fundamental
- Price
- SKK $0.72
- ABP $0.29
- Analyst Decision
- SKK
- ABP Strong Buy
- Analyst Count
- SKK 0
- ABP 1
- Target Price
- SKK N/A
- ABP $4.00
- AVG Volume (30 Days)
- SKK 121.6K
- ABP 184.6K
- Earning Date
- SKK 02-14-2025
- ABP 05-18-2025
- Dividend Yield
- SKK N/A
- ABP N/A
- EPS Growth
- SKK N/A
- ABP N/A
- EPS
- SKK N/A
- ABP N/A
- Revenue
- SKK $8,631,000.00
- ABP $183,000.00
- Revenue This Year
- SKK N/A
- ABP N/A
- Revenue Next Year
- SKK N/A
- ABP N/A
- P/E Ratio
- SKK N/A
- ABP N/A
- Revenue Growth
- SKK N/A
- ABP 50.00
- 52 Week Low
- SKK $0.61
- ABP $0.23
- 52 Week High
- SKK $11.45
- ABP $13.00
- Technical
- Relative Strength Index (RSI)
- SKK N/A
- ABP N/A
- Support Level
- SKK N/A
- ABP N/A
- Resistance Level
- SKK N/A
- ABP N/A
- Average True Range (ATR)
- SKK 0.00
- ABP 0.00
- MACD
- SKK 0.00
- ABP 0.00
- Stochastic Oscillator
- SKK 0.00
- ABP 0.00
About SKK SKK HOLDINGS LIMITED
SKK Holdings Ltd is a civil engineering service provider that specializes in subsurface utility works in Singapore. It construct and maintain various public works and infrastructure projects that serve the society and the environment. Its projects are primarily the subsurface work related to projects undertaken by the Public Utilities Board (PUB) and Singapore Telecommunications Limited. The nature of these projects is related to repairing of pumping mains, sewer maintenance and pipe cable laying.
About ABP Abpro Holdings Inc Common Stock
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms, The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with global pharmaceutical and research institutions.